EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 41 (Novembre 2025) Hors série n° 2 Med Sci (Paris), 41 (2025) 58-63 References
Free Access
Issue
Med Sci (Paris)
Volume 41, Novembre 2025
Les Cahiers de Myologie
Page(s) 58 - 63
Section Prix SFM
DOI https://doi.org/10.1051/medsci/2025182
Published online 28 November 2025
  1. Meyer A, Lannes B, Goetz J, et al. Inflammatory myopathies: A new landscape. Joint Bone Spine 2018 ; 85 (1) : 23–33. [Google Scholar]
  2. Alemo Munters L, Dastmalchi M, Andgren V, et al. Improvement in Health and Possible Reduction in Disease Activity Using Endurance Exercise in Patients With Established Polymyositis and Dermatomyositis: A Multicenter Randomized Controlled Trial With a 1-Year Open Extension Followup: Health and Disease Activity After Endurance Exercise in PM/DM. Arthritis & Rheumatism 2013 ; 65 (12) : 1959–68. [Google Scholar]
  3. Miller FW. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology 2001 ; 40 (11) : 1262–73. [Google Scholar]
  4. Rider LG. Assessment of disease activity and its sequelae in children and adults with myositis. Current Opinion in Rheumatology 1996 ; 8 (6) : 495–506. [Google Scholar]
  5. Sanner H, Gran JT, Sjaastad I, et al. Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset. Rheumatology (Oxford) 2009 ; 48 (12) : 1541–7. [Google Scholar]
  6. Mathiesen P, Hegaard H, Herlin T, et al. Long-term outcome in patients with juvenile dermatomyositis: a cross-sectional follow-up study. Scand J Rheumatol. 2012 ; 41 (1) : 50–8. [Google Scholar]
  7. Rider LG, Lachenbruch PA, Monroe JB, et al. Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum. 2009 ; 60 (11) : 3425–35. [Google Scholar]
  8. Bronner IM, van der Meulen MFG, de Visser M, et al. Long-term outcome in polymyositis and dermatomyositis. Annals of the Rheumatic Diseases 2006 ; 65 (11) : 1456–61. [Google Scholar]
  9. Alexanderson H, Dastmalchi M, Esbjörnsson-Liljedahl M, et al. Benefits of intensive resistance training in patients with chronic polymyositis or dermatomyositis. Arthritis Rheum. 2007 ; 57 (5) : 768–77. [Google Scholar]
  10. Loell I, Lundberg I. Nutrition and Polymyositis and Dermatomyositis. Coleman LA, editor. Nutrition and Rheumatic Disease. Humana Press 2008. pp. 195–213. [Google Scholar]
  11. Meyer A, Scirè CA, Talarico R, et al. Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines [corrected]. RMD Open 2019 ; 4 (Suppl 1) : e000784. [Google Scholar]
  12. Rider LG, Werth VP, Huber AM, et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ). Arthritis Care Res. 2011 ; 63 (S11) : S118–57. [Google Scholar]
  13. Malartre S, Bachasson D, Mercy G, et al. MRI and muscle imaging for idiopathic inflammatory myopathies. Brain Pathol. 2021 ; 31 (3) : e12954. [Google Scholar]
  14. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing 2019 ; 48 (1) : 16–31. [Google Scholar]
  15. Mally K, Trentmann J, Heller M, et al. Reliability and accuracy of segmental bioelectrical impedance analysis for assessing muscle and fat mass in older Europeans: a comparison with dual-energy X-ray absorptiometry. Eur J Appl Physiol. 2011 ; 111 (8) : 1879–87. [Google Scholar]
  16. Porto JM, Nakaishi APM, Cangussu-Oliveira LM, et al. Relationship between grip strength and global muscle strength in community-dwelling older people. Arch Gerontol Geriatr. 2019 ; 82 : 273–8. [Google Scholar]
  17. Ogawa S, Yakabe M, Akishita M. Age-related sarcopenia and its pathophysiological bases. Inflamm Regen. 2016 ; 36 : 17. [Google Scholar]
  18. Lee JH, Jun HS. Role of Myokines in Regulating Skeletal Muscle Mass and Function. Front Physiol. 2019 ; 10 : 42. [Google Scholar]
  19. Giannini M, Charles AL, Evrard C, et al. Sarcopenia assessed by DXA and hand-grip dynamometer: a potential marker of damage, disability and myokines imbalance in inflammatory myopathies. Rheumatology (Oxford) 2024 ; 63 (9) : 2503–14. [Google Scholar]
  20. Qaisar R, Karim A, Muhammad T, et al. Prediction of sarcopenia using a battery of circulating biomarkers. Sci Rep. 2021 ; 11 (1) : 8632. [Google Scholar]
  21. Li B, Hao J, Zeng J, Sauter ER. SnapShot: FABP Functions. Cell 2020 ; 182 (4) : 1066–1066.e1. [Google Scholar]
  22. Seth A, Steel JH, Nichol D, et al. The transcriptional corepressor RIP140 regulates oxidative metabolism in skeletal muscle. Cell Metab. 2007 ; 6 (3) : 236–45. [Google Scholar]
  23. Pritt ML, Hall DG, Recknor J, et al. Fabp3 as a biomarker of skeletal muscle toxicity in the rat: comparison with conventional biomarkers. Toxicol Sci. 2008 ; 103 (2) : 382–96. [Google Scholar]
  24. Lammers G, Poelkens F, van Duijnhoven NTL, et al. Expression of genes involved in fatty acid transport and insulin signaling is altered by physical inactivity and exercise training in human skeletal muscle. Am J Physiol Endocrinol Metab. 2012 ; 303 (10) : E1245–1251. [Google Scholar]
  25. Sorichter S, Mair J, Koller A, et al. Early assessment of exercise induced skeletal muscle injury using plasma fatty acid binding protein. Br J Sports Med. 1998 ; 32 (2) : 121–4. [Google Scholar]
  26. Lee SM, Lee SH, Jung Y, et al. FABP3-mediated membrane lipid saturation alters fluidity and induces ER stress in skeletal muscle with aging. Nat Commun. 2020 ; 11 (1) : 5661. [Google Scholar]
  27. Nguyen HC, Bu S, Nikfarjam S, et al. Loss of fatty acid binding protein 3 ameliorates lipopolysaccharide-induced inflammation and endothelial dysfunction. J Biol Chem. 2023 ; 299 (3) : 102921. [Google Scholar]
  28. Syed MH, Zamzam A, Khan H, et al. Fatty acid binding protein 3 is associated with peripheral arterial disease. JVS Vasc Sci. 2020 ; 1 : 168–75. [Google Scholar]
  29. Zhang L, Zhou H, Peng Q, et al. Fatty acid binding protein 3 is associated with skeletal muscle strength in polymyositis and dermatomyositis. Int J Rheum Dis. 2017 ; 20 (2) : 252–60. [Google Scholar]
  30. Gupta L, Majumder S, Aggarwal A, et al. Serum fatty acid-binding protein 3 levels differentiate active from inactive myositis and correlate with response to therapy. Indian J Rheumatol. 2020 ; 15 (6) : 187. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.